Bioxytran, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIXT research report →
Price Chart
About the company
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer.
- CEO
- David Platt
- IPO
- 2010
- Employees
- 2
- HQ
- Needham, MA, US
Get TickerSpark's AI analysis on BIXT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.14M
- P/E
- -0.67
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -0.50
- EV/EBITDA
- -0.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 94.22%
- ROIC
- 90.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-11,544-45.2%
- Op Income
- $-1,854,053
- Net Income
- $-2,123,077+10.3%
- EPS
- $-0.02-35.1%
- OCF Growth
- -844.5%
- FCF Growth
- -527.2%
- 52W High
- $0.09
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.04
- Beta
- 1.97
- RSI (14)
- 45
- Avg Volume
- 76.76K
No earnings-call transcripts are available for BIXT yet.
- Free Float
- 73.0%
- Shares Outstanding
- 98.90M
- Float Shares
- 72.21M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 25 | Hoberman Alan M | other | 38,588 |
| Aug 12, 25 | Hoberman Alan M | other | 10,417 |
| Nov 18, 25 | Hoberman Alan M | buy | 210,000 |
| Nov 14, 25 | MILANOVA RADKA | other | 38,588 |
| Aug 12, 25 | MILANOVA RADKA | other | 10,417 |
| Nov 14, 25 | CONAWAY DALE H | other | 38,588 |
| Aug 12, 25 | CONAWAY DALE H | other | 10,417 |
| Nov 14, 25 | Utter Anders | other | 38,588 |
| Oct 24, 24 | PLATT DAVID | other | 11,433,448 |
| Oct 24, 24 | PLATT DAVID | other | 14,085,410 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIXT coverage
Recent articles, reports, and earnings notes.
No research on BIXT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIXT report →Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
globenewswire.com · Aug 4
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
globenewswire.com · Jul 29
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
globenewswire.com · May 29
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
globenewswire.com · May 29
Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest
defenseworld.net · Mar 25
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
globenewswire.com · Mar 20
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
globenewswire.com · Mar 4
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
accessnewswire.com · Mar 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.